CN109965166A - A kind of production method of lentinan drink - Google Patents
A kind of production method of lentinan drink Download PDFInfo
- Publication number
- CN109965166A CN109965166A CN201910293617.XA CN201910293617A CN109965166A CN 109965166 A CN109965166 A CN 109965166A CN 201910293617 A CN201910293617 A CN 201910293617A CN 109965166 A CN109965166 A CN 109965166A
- Authority
- CN
- China
- Prior art keywords
- lentinan
- parts
- culture medium
- rejuvenation
- liquid culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001491 Lentinan Polymers 0.000 title claims abstract description 94
- 229940115286 lentinan Drugs 0.000 title claims abstract description 94
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 31
- 239000001963 growth medium Substances 0.000 claims abstract description 63
- 238000009630 liquid culture Methods 0.000 claims abstract description 39
- 230000003716 rejuvenation Effects 0.000 claims abstract description 34
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 20
- 230000003321 amplification Effects 0.000 claims abstract description 19
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 19
- 239000002609 medium Substances 0.000 claims abstract description 18
- 238000001914 filtration Methods 0.000 claims abstract description 17
- 235000015099 wheat brans Nutrition 0.000 claims description 37
- 235000013361 beverage Nutrition 0.000 claims description 31
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 30
- 235000007164 Oryza sativa Nutrition 0.000 claims description 30
- 235000009566 rice Nutrition 0.000 claims description 30
- 235000013312 flour Nutrition 0.000 claims description 29
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 26
- 240000008042 Zea mays Species 0.000 claims description 20
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 20
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 19
- 235000005822 corn Nutrition 0.000 claims description 19
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 19
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 19
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 18
- 229930006000 Sucrose Natural products 0.000 claims description 16
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 16
- 229960004793 sucrose Drugs 0.000 claims description 16
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 15
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 14
- 229920001817 Agar Polymers 0.000 claims description 11
- 239000008272 agar Substances 0.000 claims description 11
- 229940041514 candida albicans extract Drugs 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000012138 yeast extract Substances 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 10
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 10
- 235000019797 dipotassium phosphate Nutrition 0.000 claims description 10
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 8
- 244000062793 Sorghum vulgare Species 0.000 claims description 8
- 241000209140 Triticum Species 0.000 claims description 8
- 235000021307 Triticum Nutrition 0.000 claims description 8
- 235000019713 millet Nutrition 0.000 claims description 8
- 238000011081 inoculation Methods 0.000 claims description 5
- 235000012907 honey Nutrition 0.000 claims description 3
- 240000007594 Oryza sativa Species 0.000 claims 4
- 240000008620 Fagopyrum esculentum Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 34
- 239000000203 mixture Substances 0.000 abstract description 5
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000012531 culture fluid Substances 0.000 abstract 1
- 239000000686 essence Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000002054 inoculum Substances 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- 239000000047 product Substances 0.000 description 39
- 241000209094 Oryza Species 0.000 description 26
- 240000000599 Lentinula edodes Species 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 18
- 235000001715 Lentinula edodes Nutrition 0.000 description 15
- 238000002512 chemotherapy Methods 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 241000233866 Fungi Species 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 241000219051 Fagopyrum Species 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 230000035622 drinking Effects 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 244000061456 Solanum tuberosum Species 0.000 description 4
- 235000002595 Solanum tuberosum Nutrition 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000004053 quinones Chemical class 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010034038 Parotitis Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 235000007686 potassium Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010060976 Bacillus infection Diseases 0.000 description 1
- BZUNJUAMQZRJIP-UHFFFAOYSA-N CPDA Natural products OCCCCCCCCCCCCCCC(O)=O BZUNJUAMQZRJIP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 208000020061 Hand, Foot and Mouth Disease Diseases 0.000 description 1
- 208000025713 Hand-foot-and-mouth disease Diseases 0.000 description 1
- 206010019194 Head discomfort Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- YUGCAAVRZWBXEQ-UHFFFAOYSA-N Precholecalciferol Natural products C=1CCC2(C)C(C(C)CCCC(C)C)CCC2C=1C=CC1=C(C)CCC(O)C1 YUGCAAVRZWBXEQ-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010070308 Refractory cancer Diseases 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229940126530 T cell activator Drugs 0.000 description 1
- 102000000479 TCF Transcription Factors Human genes 0.000 description 1
- 108010016283 TCF Transcription Factors Proteins 0.000 description 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000006562 flour medium Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- GISJHCLTIVIGLX-UHFFFAOYSA-N n-[4-[(4-chlorophenyl)methoxy]pyridin-2-yl]-2-(2,6-difluorophenyl)acetamide Chemical compound FC1=CC=CC(F)=C1CC(=O)NC1=CC(OCC=2C=CC(Cl)=CC=2)=CC=N1 GISJHCLTIVIGLX-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a kind of production method of lentinan drink, mushroom strain, which is successively seeded in different types of rejuvenation culture medium, cultivates rejuvenation, cultivates 18~22 days in each type of rejuvenation culture medium；The strain to grow fine is accessed in fluid nutrient medium, carries out multistage amplification cultivation, every level-one 23~27 DEG C shake culture 5~7 days, every grade of inoculum concentration 10%~30%；The bacterial culture fluid that multistage amplification cultivation obtains keeps the temperature 1.5~2.5 hours at 63~67 DEG C with smudge cells, after after 80~120 mesh filter screen coarse filtrations, the filtering of 270~325 mesh filter screen essences, obtains lentinan drink.The present invention solves problem in the prior art using Liquid Culture, has evaded the side effect of Lentinan, has utmostly played the useful effect of the various composition of mushroom.
Description
Technical Field
The invention belongs to the technical field of preparation methods of edible fungus fermentation type functional foods, and particularly relates to a production method of a lentinan beverage.
Background
The mushroom has very high nutritive value, is important edible and medicinal fungi and seasonings for people, and is also a natural functional food. Shiitake contains more than ten kinds of amino acids, and 7 kinds of amino acids necessary for human body, such as isoleucine, lysine, phenylalanine, methionine, threonine, valine, etc., are contained therein. Every hundred grams of dried shiitake contains 13 grams of protein, 1.8 grams of fat, 54 grams of carbohydrate, 7.8 grams of crude fiber, 4.9 grams of crude ash, and various vitamins and mineral salts; 124 mg of calcium, 415 mg of phosphorus and 25.3 g of iron in the ash; the vitamins comprise 0.07 mg of B1 (thiamine), 1.13 mg of B2 (riboflavin), 18.9 mg of B3 (vitamin PP and nicotinic acid) and 260 mg of provitamin D (ergosterol). The mushroom has strong inhibition effect on cancer cells, the inhibition rate on mouse sarcoma S-180 is 97.5%, and the inhibition rate on ehrlich ascites tumor is 80%. Lentinus Edodes can be used for preventing and treating cancer, diabetes, pulmonary tuberculosis, infectious hepatitis, neuritis, dyspepsia, constipation, and reducing weight. The Lentinus Edodes also contains double-stranded ribonucleic acid, can induce production of interferon, and has antiviral effect.
The main components of the lentinus edodes are polysaccharides and unsaturated fatty acids, and the lentinus edodes also contains a large amount of ergosterol and mycosterol which can be converted into vitamin D, and lentinan is an effective active component extracted from high-quality lentinus edodes sporocarp and has a molecular formula as follows: (C)6H10O5) The lentinan extracted by hot water can adjust the activity of T cells with immune function in human bodies, and can reduce the capacity of methyl cholanthracene to induce tumors, researches show that the active polysaccharide ingredient β - (1 → 3) -D-glucan of lentinus edodes is effective in inhibiting heterogenous, homologous and even hereditary tumors, and the lentinan mainly treats gastric cancer, liver cancer and bladder cancer which can not be operated or recurred, can relieve symptoms by using the lentinan, improve the immune function of patients, and correct trace element imbalance, can also promote the proliferation of T, B cell lymphocytes, improve the activity of NK cells, resist viruses, protect the liver and the like, is an anticancer auxiliary drug which has the effect of immune regulation by improving the autoimmunity, and resists diseases by improving the autoimmunity is the best treatment method at present, in particular, the biological activity of the lentinan has the following advantages:
1. anti-tumor activity of lentinan
Lentinan has anti-tumor effect, and has no adverse side effects of chemotherapeutic drugs. Lentinan is induced to produce a cell factor with immunological activity after entering into the antibody, and under the comprehensive action of the cell factors, the immune system of the organism is enhanced, and the cell factor plays a role in defending and killing tumor cells.
Lentinan exerts anti-tumor activity by activating macrophages, enhancing antibody-dependent cell-induced cytotoxicity (ADDC); in addition, lentinan also dilates and bleeds the blood vessels at the tumor site, resulting in hemorrhagic necrosis and complete regression of the tumor.
2. Immunomodulation of lentinan
The immunoregulation function of lentinan is an important basis of its biological activity. Lentinan is a typical T cell activator, promotes the production of interleukins, and also promotes the function of mononuclear macrophages, and is considered to be a specific immunopotentiator. The immune function is characterized in that the immune function can promote the generation of lymphocyte activating factor (LAE), release various helper T cell factors, enhance the phagocytosis rate of host peritoneal macrophages and recover or stimulate the function of helper T cells. In addition, lentinan also promotes antibody production and inhibits macrophage release.
3. Antiviral activity of lentinan
It is considered that shiitake mushroom contains a double-stranded ribonucleic acid which stimulates reticulocytes and leukocytes of the human body to release interferon, and interferon has an antiviral effect. The Lentinus Edodes mycelium extract can inhibit cell adsorption of herpesvirus, and can be used for preventing and treating various diseases caused by herpes simplex virus and cytomegalovirus. A substance is extracted from cultured shiitake mushroom mycelia, and has effects in recovering T lymphocytes infected by AIDS virus, stimulating macrophage, and promoting antibody production to treat AIDS, with high safety and no adverse side effect.
The sulfated lentinan has been found by scholars to have activity against the Human Immunodeficiency Virus (HIV) and to interfere with the adsorption and invasion of retroviruses and other viruses. Japanese scholars reported that a sulfated derivative of dextran obtained from fruiting body of Lentinus edodes with good antitumor effect could inhibit HIV activity.
4. Lentinan anti-infection effect
Lentinan is reported to increase macrophage function. Lentinan has inhibitory action on Abelson virus, adenovirus 12 and influenza virus infection, and is a good medicine for treating various hepatitis, especially chronic migratory hepatitis.
Current applications of lentinan include:
1. application of lentinan in medicine field
Lentinan has good therapeutic effect in treating gastric cancer, colon cancer, lung cancer, etc. As an immune adjuvant, lentinan is mainly used for inhibiting the occurrence, development and metastasis of tumors, improving the sensitivity of the tumors to chemotherapeutic drugs, improving the physical condition of patients and prolonging the life of the patients.
The lentinan can be used in combination with chemotherapeutic agent, and has effects of reducing toxicity and enhancing efficacy. The selectivity of the chemotherapeutic drugs for killing tumor cells is poor, normal cells are also killed, toxic and side effects are generated, and chemotherapy cannot be performed according to the quantity in time; because of insufficient dose of chemotherapy, drug resistance of tumor cells is often caused, which becomes refractory cancer and affects the curative effect. The lentinan is taken in the chemotherapy process, so that the curative effect of chemotherapy can be enhanced, and the toxic effect of the chemotherapy can be reduced; meanwhile, the incidence rate of leucocyte reduction, gastrointestinal toxicity, liver function damage and vomiting of the patients in the chemotherapy process are obviously reduced. This fully demonstrates that the combination of lentinan with chemotherapy can enhance the efficacy, reduce the toxicity, and enhance the immune function of the patient's body.
Lentinan can be used in combination with other medicines for treating chronic hepatitis B, and can improve the negative conversion effect of hepatitis B virus marker and reduce the side effect of antiviral medicines. In addition, lentinan can be used to treat tubercle bacillus infection.
2. Application of lentinan in health food field
Lentinan is a special bioactive substance, a biological response enhancer and regulator, and can enhance humoral immunity and cellular immunity. The antiviral action mechanism of lentinan may lie in that it can raise immunity of infected cell, raise stability of cell membrane, inhibit cytopathy and promote cell repair. Meanwhile, lentinan also has anti-retroviral activity. Therefore, lentinan is a health food against influenza to be developed.
The lentinan powder and lentinan capsules which are commonly used in clinic at present have the effects of activating cellular immunity, regulating various humoral immune factors, inducing α -interferon generation, regulating organism immune response reaction, inducing leukocyte infiltration to tumor, causing vasodilatation, bleeding and necrosis of tumor parts, preventing combination of virus and host cells, improving SOD activity, inhibiting MDA generation, resisting lipid oxidation, reducing cholesterol, regulating carbohydrate metabolism, improving carbohydrate tolerance, expanding gastrointestinal tract to generate satiety, reducing appetite, reducing blood sugar and the like.
It is often combined with tegafur (FT207), Adriamycin (ADR) and mitomycin (MMC) clinically to treat the stomach cancer which can not be operated or recurred. Can also be used for treating colorectal cancer, lung cancer, breast cancer, acute and chronic leukemia, and chronic viral hepatitis B. For the patients with late stage cancer with distant organ metastasis, the composition can be used in chemotherapy to improve the general condition of patients, improve therapeutic effect, and prolong life.
But the accidental adverse reactions are as follows:
① shock is rare, so it should be closely observed after administration, and should be stopped and properly and timely treated when symptoms such as abnormal mouth, aversion to cold, abnormal heart rhythm, blood pressure drop, and dyspnea occur.
② when rash and redness occur, the medicine should be stopped in time and should be treated if necessary.
③ the respiratory system should be closely observed due to chest compression and throat stenosis, and the administration speed should be slowed down
④ nausea, emesis, and anorexia.
⑤ headache, heaviness of head and dizziness in nervous system.
⑥ decrease of blood, occasional red, white blood cells and hemoglobin.
⑦ and other symptoms such as fever, sweating, and flushing.
Lentinan products are various, and mainly comprise injections, capsules, tablets, powder and the like on the market, lentinan powder and lentinan capsules are commonly used clinically, most products are extracted from lentinan sporocarp, the workload is large, the efficiency is low, the cost is high, the pollution is serious, the price is high, and adverse reactions such as shock, rash, nausea, vomiting, inappetence, dizziness and the like can be found when the lentinan capsules are taken. In addition, probably because the strain is degraded quickly, the technical difficulty of the production process is large, and the requirement on technical personnel is high, products of lentinan drinks (liquid beverages) are not seen so far, and in patent applications related to lentinan, the methods for producing the lentinan by liquid are few, and only tests in laboratories have not been reported, and no large-scale production is reported. Therefore, there is a need for further improvement of health food of shiitake mushroom and a method for preparing the same, and providing a more effective, safer, mass-producible product.
Disclosure of Invention
The invention aims to overcome the defects of the prior art, provides a production method of lentinan beverage, solves the problems in the prior art by adopting liquid culture, avoids the side effect of lentinan capsules, and exerts the effective effect of various components of lentinus edodes to the maximum extent.
The technical scheme adopted by the invention for solving the technical problems is as follows:
a production method of lentinan beverage comprises sequentially inoculating Lentinus edodes strains to different types of rejuvenation culture medium for culturing for rejuvenation, and culturing in each type of rejuvenation culture medium for 18-22 days; inoculating strains with good growth vigor into a liquid culture medium, and performing multi-stage amplification culture, wherein each stage is subjected to shake culture at 23-27 ℃ for 5-7 days, and the inoculation amount of each stage is 10% -30%; performing multi-stage amplification culture to obtain a thallus culture solution, preserving heat for 1.5-2.5 hours at 63-67 ℃ to break cells, and then performing coarse filtration by using a 80-120 mesh filter screen and fine filtration by using a 270-325 mesh filter screen to obtain a lentinan beverage; wherein,
the rejuvenation culture medium comprises the following components in parts by weight: 28-32 parts of corn flour or wheat flour or millet flour or buckwheat flour, 18-22 parts of cane sugar, 18-22 parts of wheat bran, 18-22 parts of rice bran, 2-4 parts of monopotassium phosphate, 2-4 parts of dipotassium hydrogen phosphate, 1-2 parts of magnesium sulfate, 2-4 parts of yeast extract and 28-32 parts of agar;
the liquid culture medium comprises the following components in parts by weight: 28-32 parts of corn flour, 18-22 parts of cane sugar, 18-22 parts of wheat bran, 18-22 parts of rice bran, 2-4 parts of monopotassium phosphate, 2-4 parts of dipotassium phosphate, 1-2 parts of magnesium sulfate and 2-4 parts of yeast extract.
In one embodiment: the rejuvenation culture medium comprises the following components in proportion by formula: 30 g of corn flour, wheat flour, millet flour or buckwheat flour, 20 g of cane sugar, 20 g of wheat bran, 20 g of rice bran, 3 g of monopotassium phosphate, 3 g of dipotassium phosphate, 1.5 g of magnesium sulfate, 3 g of yeast extract, 30 g of agar and 1000 ml of water.
In one embodiment: the liquid culture medium comprises the following components in proportion by formula: 30 g of corn flour, 20 g of cane sugar, 20 g of wheat bran, 20 g of rice bran, 3 g of monopotassium phosphate, 3 g of dipotassium phosphate, 1.5 g of magnesium sulfate, 3 g of yeast extract and 1000 ml of water.
In one embodiment: the multi-stage amplification culture is 3-6 stages of amplification.
In one embodiment: the specific method for multistage amplification culture comprises the following steps: taking out a strain from a rejuvenation culture medium, inoculating the strain into 45-55 ml of liquid culture medium, transferring a product obtained by culturing the 45-55 ml of liquid culture medium into 240-260 ml of liquid culture medium, transferring a product obtained by culturing the 240-260 ml of liquid culture medium into 480-520 ml of liquid culture medium, and transferring a product obtained by culturing the 480-520 ml of liquid culture medium into 1400-1600 ml of liquid culture medium.
In one embodiment: after the filtration, honey is added to adjust the taste.
In one embodiment: the lentinan beverage is sterilized and filled to obtain a finished product.
In one embodiment: the rejuvenation medium is sterilized at 120-126 ℃ for 25-35 minutes before use.
In one embodiment: the liquid culture medium is sterilized at 120-126 ℃ for 25-35 minutes before use.
Compared with the background technology, the technical scheme has the following advantages:
A. the invention performs rejuvenation through multi-stage culture, and solves the problem of product quality reduction caused by easy degeneration of strains;
B. according to the invention, natural cereal rice bran and wheat bran are used as culture media to replace chemically synthesized vitamins added in a liquid culture medium, so that the quality of the product is improved, and the product is safer;
C. the invention carries out multistage amplification in a shorter culture period, thereby reducing the production cost;
D. the invention breaks the cells at lower temperature and extracts, so that the product can keep the biological activity of the effective components to a greater extent;
E. the invention adopts multi-stage filtration, which not only reduces the difficulty of filtration and keeps the effective components of the product, but also ensures that the appearance and the taste of the product are better.
F. The method adopts liquid culture to produce lentinan beverage, and retains various effective components of Lentinus Edodes such as polysaccharide, polypeptide, quinones, etc. The invention enriches the variety of lentinan products. The beverage not only can replace powder and capsules, but also can avoid adverse reaction caused by taking the lentinan capsules and the powder because the product is pure natural and is not added with other additives, and other components in the lentinan such as polypeptide, quinones and the like can play a wider role in treating and preventing other types of diseases such as virus diseases than single lentinan component. The application feedback information shows that after the product is drunk, the immunity is improved, the appetite is increased, the bowel is well relaxed, the vigor is vigorous, the improvement of leucocytes after chemotherapy is facilitated, the sleep is improved and reduced, even analgesic drugs and nerve-soothing drugs are not used, and the lentinan drink fed back by a plurality of patients has good effects on preventing and treating virus diseases.
Drawings
The invention is further illustrated by the following figures and examples.
FIG. 1 is a photograph showing the effect of the culture of the medium supplemented with wheat bran and rice bran and the rest of the medium, wherein the control group, VB1 group, wheat bran group and rice bran group are not added, respectively, from left to right.
FIG. 2 is a second photograph showing the results of the culture in the medium supplemented with wheat bran and rice bran and the rest of the medium, wherein the control group, VB1 group, wheat bran group and rice bran group are shown from left to right.
FIG. 3 is a third photograph showing the three culture effects of the medium supplemented with wheat bran and rice bran and the rest of the medium, wherein the group supplemented with wheat bran and rice bran, the control group not supplemented with wheat bran, the group supplemented with VB1 and the group supplemented with wheat bran are shown from left to right.
FIG. 4 is a fourth photograph showing the results of the culture in the medium supplemented with wheat bran and rice bran and the rest of the medium, wherein the control group, the VB1 group, the rice bran group, the wheat bran and rice bran group, and the wheat bran and rice bran group are shown from left to right.
Detailed Description
The present invention will be described in detail with reference to the following examples:
a production method of lentinan beverage comprises inoculating Lentinus edodes strain into rejuvenation culture medium of different types, and culturing for 18-22 days to rejuvenate the strain; inoculating the strains with good growth after rejuvenation into a liquid culture medium, and performing multi-stage amplification culture, wherein each stage is subjected to shake culture at 25 ℃ for 5-7 days, and the inoculation amount of each stage is 10% -30%; and (3) preserving the heat of a thallus culture solution obtained by multistage amplification culture at 65 ℃ for 2 hours to break cells, releasing substances such as lentinan, polypeptide, protein, enzyme, quinones and the like in the cells, performing coarse filtration by using a 100-mesh filter screen and fine filtration by using a 300-mesh filter screen, adding a small amount of honey according to needs to adjust the taste, sterilizing, and filling into a 100-milliliter bottle to obtain a lentinan beverage finished product.
Wherein,
the rejuvenation culture medium comprises the following components: 30 g of corn flour, wheat flour, millet flour or buckwheat flour, 20 g of cane sugar, 20 g of wheat bran, 20 g of rice bran, 3 g of monopotassium phosphate, 3 g of dipotassium phosphate, 1.5 g of magnesium sulfate, 3 g of yeast extract and 30 g of agar, adding 1000 ml of water, uniformly mixing, heating to dissolve, cooling to solidify, and sterilizing for 30 minutes at 121 ℃.
The formula of the liquid culture medium is as follows: 30 g of corn flour, 20 g of cane sugar, 20 g of wheat bran, 20 g of rice bran, 3 g of monopotassium phosphate, 3 g of dipotassium phosphate, 1.5 g of magnesium sulfate and 3 g of yeast extract, adding 1000 ml of water, uniformly mixing, and sterilizing for 30 minutes at 121 ℃.
The method of the invention is characterized in that:
A. rejuvenating strains are alternately used by the starch components of the culture medium, such as millet, corn, buckwheat, wheat and the like, so that the problems of fast strain degeneration and product quality reduction are solved; the mushroom fungus is degraded quickly in the culture process, seriously affects the quality of products and is difficult to continuously produce. By using a plurality of culture mediums alternately, the problem of product quality reduction caused by strain degeneration is solved by using a rejuvenation method, so that the strain with stronger activity is used every time, and the product quality is ensured.
The strain is preserved for a long time, the strain is used for a long time and the number of times of tube transfer is too many, so the strain rejuvenation work is required, and the rejuvenation method comprises the following steps: separating and purifying, activating and transplanting, replacing culture medium, and changing culture medium with different formula can enhance new vitality and promote good seed rejuvenation. The strain is from a strain purchased by mushroom farmers from the fungus institute of Sanming City, the strain with good growth vigor is taken from the mushroom farmers, the mushroom strain is inoculated into different (corn, buckwheat, millet and wheat) solid rejuvenation culture mediums for culture, each culture medium is cultured for about 20 days, the strain with good growth vigor is screened for seed preservation and production, and the strain with good growth vigor is inoculated into a liquid culture medium sterilized at 121 ℃ for 30 minutes for multistage amplification culture. The sequence and frequency of use of the rejuvenation media of various types are not limited. For example, in this embodiment, mushroom strains are first cultured in a maize rejuvenation medium for 20 days, strains with good growth vigor are selected and transplanted into a wheat rejuvenation medium for 20 days, strains with good growth vigor are selected and transplanted into a millet rejuvenation medium for 20 days, and strains with good growth vigor are selected and transplanted into a buckwheat rejuvenation medium for 20 days to achieve the purpose of rejuvenation.
B. The formula of the liquid culture medium is as follows: 30 g of corn flour, 20 g of cane sugar, 20 g of wheat bran, 20 g of rice bran, 3 g of monopotassium phosphate, 3 g of dipotassium phosphate, 1.5 g of magnesium sulfate, 3 g of yeast extract and 1000 ml of water. The formula of the liquid culture medium is obtained by comprehensively adjusting the dosage and combination of starch, sugar, potassium and magnesium ions, vitamins, wheat bran, rice bran and other components on the basis of the solid culture medium in the prior art. (the formulation screening protocol is shown in attached table 1 and 2)
In the tests, when more than 30 grams of corn flour were used in the formula, the corn flour medium was not used up, whereas less than 30 grams of corn flour had less edible fungal mass in the culture broth, and the culture medium was not as required for different culture times, 30 grams of corn flour per liter being selected in the formula of the invention.
The results of tests on the amounts of sucrose, glucose, wheat bran, potassium phosphate, etc. shown in the attached Table 1 are: the edible fungi cultured by the sucrose and the glucose have little difference in results, and the cost of the sucrose is lower; the wheat bran has a higher utilization rate of 20 grams per liter; the dosage of the potassium dihydrogen phosphate and the dipotassium hydrogen phosphate has certain influence on the quantity and the size of the thalli.
Table 2 attached hereto, in order to solve the influence of the potassium dihydrogen phosphate and the dipotassium hydrogen phosphate on the edible fungus mass, the present invention has further experiments, and the experimental results show that the amount of the dipotassium hydrogen phosphate affects the growth of the edible fungus mass, and when the amount of the dipotassium hydrogen phosphate is large, the edible fungus mass is small and large, so that in the production, when a large number of breeding generations are needed, the edible fungus mass can be adjusted by adjusting the amount of the potassium. Conversely, the amount of dipotassium phosphate can be reduced when smaller edible fungus clusters are required. The test shows that 3 g of potassium dihydrogen phosphate and 3 g of dipotassium hydrogen phosphate are used per liter.
Attached table 1: one of the culture medium formulation screens
Attached table 2: comparison of the amounts of Potassium dihydrogen phosphate, dipotassium Hydrogen phosphate and wheat bran
The wheat bran and the rice bran are added into the liquid culture medium, so that the quality of the product is improved; when a producer cultures mushroom strains, a PDA culture medium (200 g of potatoes, 20 g of glucose, 20 g of agar and 1000 ml of water) is mostly adopted; PSA medium (potato 200 g, sucrose 20 g, agar 20 g, water 1000 ml); the culture of the mother strain of shiitake mushroom (authored by Zhang Bao Jun from Shii Xiang Mushroom culture Utility technology) was carried out in a CPDA medium (potato 200 g, glucose 20 g, agar 20 g, potassium dihydrogen phosphate 2 g, magnesium sulfate 0.5 g, and water 1000 ml) or the like, but the liquid medium was prepared in the above formulation without adding agar. The shiitake liquid culture medium in the 'mushroom production technology book' compiled by Chen Shi Yu has five formulas: 1. wheat bran 5%, glucose 2%, ammonium sulfate 0.1%, magnesium sulfate 0.04%, zinc sulfate 0.02%, boric acid 0.01%, gypsum powder 1%, vitamin B121 ml, agar 0.05%, and natural pH; 2. 20% of potato, 2% of glucose, 0.2% of ammonium sulfate, 0.1% of monopotassium phosphate, 0.05% of magnesium sulfate, 110 mg/1L of vitamin B, 0.05% of agar and natural pH; 3. 7-9% of soluble starch, 1% of glucose, 1.5-2% of corn steep liquor, 0.1% of monopotassium phosphate and 9 mg/L of zinc sulfate; 4. 90% of citric acid fermentation wastewater (containing 1.5% of sugar), 8% of wheat bran leachate, 1% of sweet potato powder and pH 6.5; 5. 3% of sucrose, 0.1% of monopotassium phosphate, 0.1% of magnesium sulfate, 5% of wheat bran leachate, 0.3% of corn steep liquor and pH 6.5. Some mushroom farmers add rice bran and wheat bran into the solid culture medium, the operation is troublesome, the pollution is easy, the drinking taste is influenced, and no rice bran component is added into the formula of the liquid culture medium. The wheat bran and rice bran which are difficult to eat and absorb for human are effectively absorbed and transformed by edible fungi and then are supplied to human for eating (see attached table 3 and attached drawing).
An accessory 3: one of multiple comparative experiments with wheat bran and rice bran
Note: as can be seen from the figure, the culture medium has the same components, and the growth vigor of the strain added with the wheat bran and the rice bran is better than that of the strain added with VB1 compared with that of the control without the wheat bran, and the growth vigor of the strain added with the wheat bran is slightly worse than that of the culture solution added with the rice bran solution.
C. Multi-stage amplification is carried out in a shorter time, so that the production cost is reduced; because the production link needs to carry out multi-stage amplification on strains, each stage of growth cycle of the strains needs a certain time, and each batch of products needs more than two months from inoculation to liquid culture medium to becoming products, the production time of the products is long, and the cost is high. The invention explores a method for simultaneously carrying out amplification culture of a plurality of levels in a plurality of stages, namely taking out strains from a rejuvenated solid culture medium and inoculating the strains into 50 ml of liquid culture medium, inoculating 50 ml of cultured liquid strains into 250 ml of liquid culture medium, inoculating 250 ml of liquid strains into 500 ml of liquid culture medium, and inoculating 500 ml of liquid strains into 1500 ml of liquid culture medium. The inoculation amount of each level is about 10-30% (namely after the strain product obtained by each level of cultivation is collected, 10-30% (mass percentage) of the strain product is inoculated into the next level of culture medium for next level of cultivation), and each level of cultivation is performed in a shaking table at 25 ℃ for 7 days. Four-stage culture is carried out simultaneously by a plurality of culture boxes or one culture box, so that the biological activity of the strain is ensured, the production time is shortened, and the production cost is reduced.
D. The cells are broken after the temperature is kept at 65 ℃ for hours, and the extraction is carried out, so that the product can keep the biological activity of the effective components to a greater extent; most producers use a high-temperature method to break cells and release substances in the cells, but the high temperature can cause the loss or reduction of the activity of active ingredients in the mushroom culture solution, such as enzyme, polysaccharide, polypeptide and protein, and the degradation of the active ingredients of the mushrooms, so that the products cannot play the best role. The invention can break and extract cell at lower temperature, to keep the biological activity of the effective component of liquid mushroom fungus. In the prior art, the pH value is adjusted to be alkaline for the consideration of product appearance, so that the generation of precipitate is prevented. The mushroom can grow at the pH value of 3-7, but the mushroom is in preference to an acidic environment. The invention finds that the lentinan beverage has better effect in slightly acidic environment, and although the product has precipitate and poor appearance, the lentinan beverage is beneficial to the function of the effective components in the product, so that the pH value does not need to be adjusted to be alkaline as in the prior art.
E. The taste of the product is better by adopting multi-stage filtration; the crushed liquid mushroom has more cell residues, high viscosity and higher filtering difficulty. The invention discovers that the crushed liquid is subjected to coarse filtration by a 100-mesh filter screen and fine filtration by a 300-mesh filter screen, so that the difficulty in filtration is reduced, the effective components of the product are retained, and the appearance and the taste of the product are better.
Due to the pollution of living environment, cancer patients are more and more, and modern medicine finds that one cancer patient is generated every six seconds. The invention brings good news to cancer patients, and the price is lower than that of lentinan powder, and the effective components are higher. Has good economic benefit and social benefit. The invention has been carried out for years of small-batch production and test, has good effect, has started to carry out the construction of the production line of large-scale production and the exploration of the production expansion condition, and can be used for industrialized production.
Through more than seven years of experiments, people drinking the product have cancer patients such as liver cancer, lung cancer, breast cancer, colon cancer, bladder cancer, stomach cancer, thyroid cancer and the like; has obvious relieving effect on infants, children and old people suffering from influenza, parotitis, hand-foot-and-mouth disease, and related symptoms such as senile asthma, allergy and the like, and has no adverse reaction.
Case 1 patient mr. forest: the lentinan drink is born in 1957, diagnosed as primary liver cancer in Fujian province coordination hospitals in 2009 at 9 months, and drunk during treatment and rehabilitation, and from 2012 at 6 months till now, 2 bottles of lentinan drinks are basically obtained every day, so that the taste is good. Compared with the prior art, the medicine is less prone to fatigue, has less possibility of catching cold and can quickly recover the body after treatment. In recent years, after repeated examinations, the disease condition is stable, the life is normal, and the activity is free. The lentinan drink is described by patients and is helpful for enhancing body immunity, stabilizing illness state and recovering health.
Case 2 patients were lady every week: the patient is born in 1958, diagnosed as left lung squamous carcinoma in Fujian province tumor hospital in 2012 and 6 months, and controlled by four courses of chemotherapy and one course of radiotherapy. During the treatment and later recovery period, from 6 months to the present in 2012, 2 bottles of lentinan beverage are constantly drunk every day, and people are not tired, spirited and easy to catch a cold after drinking. The disease condition is stable all the time for many years, the condition is good, and the life quality is good. The patients can drink the lentinan drink by themselves, which is helpful for improving the immunity of the body, stabilizing the state of illness and improving the physical condition.
Case 3 patients were women in king: the diagnosis of differentiated adenocarcinoma in ascending colon was confirmed in Zhongshan Hospital, Xiamen City, in 2016, 12 months after birth in 1927. Considering that the age is older, the operation treatment is refused, the conservative therapy is selected, and 2 bottles of lentinan drinks are drunk every day from 2016, 12, 25 and the like, so that the feeling is good. When drinking is started, the excrement is smoother every day than before, and the defecation is timed without adverse side effects. At present, the life is as before the disease, the appetite is good, the hematochezia is not found, and the life moves freely.
Case 4 patient zheng lady: thyroid tumor was detected at the end of 1966, and in 2015, papillary carcinoma was detected in 2016 after 2 months of surgery, and lentinan drink was drunk from the beginning of surgery. 2 bottles are drunk when a person feels no strength after operation, 1 bottle is drunk every day when the state before the operation is recovered, and the rest two or three days are intermitted sometimes in the middle. After the patient feels full physical strength and enhanced resistance after taking the tablet, no cold exists after drinking the tablet for more than two years, doctors require that the dosage of the left sodium thyroxine tablet is reduced from 200 micrograms to 50 micrograms every day, and all indexes of the body are in a control range.
Case 5 patients wu women: the birth in 1963, the bone metastasis of the breast cancer in 2016 in 2013 due to the breast cancer operation, and the cancer receiving chemotherapy treatment in the second department of tumors of Fuzhou general college in the army area of Nanjing. After patients take the lentinan oral liquid continuously after chemotherapy for three times, the white blood cell index is kept at a normal value all the time, and the red blood cells are also increased on the original basis. If the lentinan oral liquid is not continuously used, the physical strength is obviously reduced, and the lentinan oral liquid is easy to fatigue, poor in sleep and poor in appetite, and particularly the blood pressure is reduced to 86/55.
Case 6 patients had women: the product is born in 1949, breast cancer is confirmed in 2018 in month 4, and 2 bottles of lentinan beverage are drunk every day from month 6, so that the product has good feeling and is free to live and move.
Case 7 patient mr. wang: when the patient is about 65 years old and suffers from liver cancer of 25 centimeters and takes 2 bottles every day, the subjective symptoms of the patient are continuously improved or reduced earlier, wherein the most obvious symptoms are that the liver area is not painful, other symptoms are also obviously improved and reduced, and particularly the sleep condition is obviously improved. The lentinan beverage can reduce pain and improve life quality, a patient can only lie in bed before taking the lentinan beverage, and morphine and hypnotic drugs are reduced or stopped taking the lentinan beverage, so that the patient can walk to achieve the aim of final care.
Case 8 patients had plum women: two whitening needles are needed to be made every week before the lentinan beverage is taken, and the whitening needles are not needed to be made after the lentinan beverage is taken.
In case 9, the surgery of salpingitis of pet was performed, the number of leukocytes before surgery was 3.6 ten thousand, the lentinan drink was drunk 3 days after surgery, 100 ml per day, the leukocytes were increased to 4.6 ten thousand on the third day, and the leukocytes were recovered to 6 thousand after the drinking was stopped for 3 days.
Most patients are expected to have different degrees of effectiveness in trying about 50 cancer patients and 80 other patients. The cold prevention and treatment effects on viruses such as mouth, foot and hand diseases, parotitis, influenza and the like of children are obvious; has obvious physique strengthening effect on patients with senile bronchitis, asthma patients and old and weak people; has obvious effects of increasing leucocyte, enhancing immunity, improving sleep quality, increasing appetite and the like after radiotherapy and chemotherapy of cancer patients.
The above description is only a preferred embodiment of the present invention, and therefore should not be taken as limiting the scope of the invention, which is defined by the appended claims and their equivalents.
Claims (9)
1. A production method of lentinan beverage is characterized in that: sequentially inoculating mushroom strains to different types of rejuvenation culture media for culturing and rejuvenating, wherein each type of rejuvenation culture medium is cultured for 18-22 days; inoculating strains with good growth vigor into a liquid culture medium, and performing multi-stage amplification culture, wherein each stage is subjected to shake culture at 23-27 ℃ for 5-7 days, and the inoculation amount of each stage is 10% -30%; performing multi-stage amplification culture to obtain a thallus culture solution, preserving heat for 1.5-2.5 hours at 63-67 ℃ to break cells, and then performing coarse filtration by using a 80-120 mesh filter screen and fine filtration by using a 270-325 mesh filter screen to obtain a lentinan beverage; wherein,
the rejuvenation culture medium comprises the following components in parts by weight: 28-32 parts of corn flour or wheat flour or millet flour or buckwheat flour, 18-22 parts of cane sugar, 18-22 parts of wheat bran, 18-22 parts of rice bran, 2-4 parts of monopotassium phosphate, 2-4 parts of dipotassium hydrogen phosphate, 1-2 parts of magnesium sulfate, 2-4 parts of yeast extract and 28-32 parts of agar;
the liquid culture medium comprises the following components in parts by weight: 28-32 parts of corn flour, 18-22 parts of cane sugar, 18-22 parts of wheat bran, 18-22 parts of rice bran, 2-4 parts of monopotassium phosphate, 2-4 parts of dipotassium phosphate, 1-2 parts of magnesium sulfate and 2-4 parts of yeast extract.
2. The method for producing a lentinan beverage according to claim 1, wherein: the rejuvenation culture medium comprises the following components in proportion by formula: 30 g of corn flour, wheat flour, millet flour or buckwheat flour, 20 g of cane sugar, 20 g of wheat bran, 20 g of rice bran, 3 g of monopotassium phosphate, 3 g of dipotassium phosphate, 1.5 g of magnesium sulfate, 3 g of yeast extract, 30 g of agar and 1000 ml of water.
3. The method for producing a lentinan beverage according to claim 1, wherein: the liquid culture medium comprises the following components in proportion by formula: 30 g of corn flour, 20 g of cane sugar, 20 g of wheat bran, 20 g of rice bran, 3 g of monopotassium phosphate, 3 g of dipotassium phosphate, 1.5 g of magnesium sulfate, 3 g of yeast extract and 1000 ml of water.
4. The method for producing a lentinan beverage according to claim 1, wherein: the multi-stage amplification culture is 3-6 stages of amplification.
5. The method for producing a lentinan beverage according to claim 1, wherein: the specific method for multistage amplification culture comprises the following steps: taking out a strain from a rejuvenation culture medium, inoculating the strain into 45-55 ml of liquid culture medium, transferring a product obtained by culturing the 45-55 ml of liquid culture medium into 240-260 ml of liquid culture medium, transferring a product obtained by culturing the 240-260 ml of liquid culture medium into 480-520 ml of liquid culture medium, and transferring a product obtained by culturing the 480-520 ml of liquid culture medium into 1400-1600 ml of liquid culture medium.
6. The method for producing a lentinan beverage according to claim 1, wherein: after the filtration, honey is added to adjust the taste.
7. The method for producing a lentinan beverage according to claim 1, wherein: the lentinan beverage is sterilized and filled to obtain a finished product.
8. The method for producing a lentinan beverage according to claim 1, wherein: the rejuvenation medium is sterilized at 120-126 ℃ for 25-35 minutes before use.
9. The method for producing a lentinan beverage according to claim 1, wherein: the liquid culture medium is sterilized at 120-126 ℃ for 25-35 minutes before use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910293617.XA CN109965166A (en) | 2019-04-12 | 2019-04-12 | A kind of production method of lentinan drink |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910293617.XA CN109965166A (en) | 2019-04-12 | 2019-04-12 | A kind of production method of lentinan drink |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109965166A true CN109965166A (en) | 2019-07-05 |
Family
ID=67084473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910293617.XA Pending CN109965166A (en) | 2019-04-12 | 2019-04-12 | A kind of production method of lentinan drink |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109965166A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112602663A (en) * | 2020-11-25 | 2021-04-06 | 云南酱香农业科技开发有限公司 | Disease prevention method in ecological pig breeding |
| CN116018144A (en) * | 2020-06-15 | 2023-04-25 | 玛希敦大学 | An antiviral pharmaceutical composition containing therapeutic agent derived from Astraeus Asiaticus |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1078872A (en) * | 1993-05-20 | 1993-12-01 | 田子成 | Health drink prepared by mushroom double bacteria liquid fermentation method |
| CN104856150A (en) * | 2015-04-26 | 2015-08-26 | 哈尔滨伟平科技开发有限公司 | Manufacturing method of lentinan health-care beverage |
| CN108967038A (en) * | 2018-08-28 | 2018-12-11 | 铜陵盛牛菌业有限责任公司 | A kind of method of liquid strain cultivation mushroom |
-
2019
- 2019-04-12 CN CN201910293617.XA patent/CN109965166A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1078872A (en) * | 1993-05-20 | 1993-12-01 | 田子成 | Health drink prepared by mushroom double bacteria liquid fermentation method |
| CN104856150A (en) * | 2015-04-26 | 2015-08-26 | 哈尔滨伟平科技开发有限公司 | Manufacturing method of lentinan health-care beverage |
| CN108967038A (en) * | 2018-08-28 | 2018-12-11 | 铜陵盛牛菌业有限责任公司 | A kind of method of liquid strain cultivation mushroom |
Non-Patent Citations (5)
| Title |
|---|
| 崔颂英等: "食用菌母种制作技术的几点改进", 《食用菌》 * |
| 张宝军: "《香菇栽培实用新技术》", 31 August 2017, 金盾出版社 * |
| 曾虹燕等: "《生物化学实验》", 31 October 2014, 湘潭大学出版社 * |
| 朱研静等: "香菇保健饮料的研制", 《食用菌》 * |
| 魏银初等: "《香菇栽培实操技术图解》", 30 November 2014, 中原农民出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116018144A (en) * | 2020-06-15 | 2023-04-25 | 玛希敦大学 | An antiviral pharmaceutical composition containing therapeutic agent derived from Astraeus Asiaticus |
| CN112602663A (en) * | 2020-11-25 | 2021-04-06 | 云南酱香农业科技开发有限公司 | Disease prevention method in ecological pig breeding |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104829738B (en) | Application of sargassum graminifolium polysaccharide extract in improvement of intestinal flora and prevention and treatment of diabetes | |
| CN101965969B (en) | Health-care food composition with anti-fatigue and immunity-improving functions and preparation method and application thereof | |
| CN105658227B (en) | Composition for preventing and treating cancer-induced fatigue containing processed ginseng powder or processed ginseng extract with increased ginsenoside content | |
| CN101711858B (en) | Medicine for treating cancer | |
| CN106107463A (en) | Super Quinoa Antifatigue milk tea processing technology | |
| CN106551378A (en) | A kind of compositionss of probiotics fermention Cordyceps militaris (L.) Link. and its preparation method and application | |
| CN102160664A (en) | Nutritious drink for children | |
| CN102755346A (en) | Compound polysaccharide formula of edible fungus as well as preparation method and application thereof | |
| CN102090563B (en) | Relaxing and sleeping health-care food and preparation method thereof | |
| CN106616947A (en) | Cordyceps militaris composition | |
| CN109965166A (en) | A kind of production method of lentinan drink | |
| CN109452634B (en) | Fungus symbiotic fermentation blood sugar-reducing moringa oleifera and preparation method thereof | |
| CN106720683A (en) | A kind of method for preparing functional black tea bacteria beverage as raw material with matrimony vine honeysuckle black tea | |
| CN102726665B (en) | Method for producing corn flour by the solid state fermentation of maize pulp by using edible fungi | |
| CN110423699A (en) | A kind of mycelium liquid fermentation medium composition of selenium-rich agaric and preparation method thereof and fermentation process | |
| EP2842433B1 (en) | Food for nutritional therapy of aids | |
| CN107007646A (en) | A kind of nutrition compound of assisting in preventing and treating cancer | |
| CN108497240B (en) | Compound fruit vinegar beverage with auxiliary blood sugar reducing function and preparation method thereof | |
| CN103262980A (en) | Selenium germanium chromium elements-enriched vitamin spirulina health-care rice flour | |
| CN103070333B (en) | Cordyceps militaries (active substance) polysaccharide extraction and capsule preparation method | |
| CN104287045A (en) | Large green date and tea fungus beverage | |
| CN104017715A (en) | Passion fruit vinegar and preparation method thereof | |
| CN1255052C (en) | Food containing vitamines and trace elements | |
| CN107484547B (en) | Method for culturing Cordyceps militaris by using culture medium prepared from vaccinium bracteatum leaves as main material | |
| CN101129406A (en) | Formula of compound colla carapaeis corii asini series products and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190705 |
|
| RJ01 | Rejection of invention patent application after publication |